Bulletin of Environment, Pharmacology and Life Sciences
Bull. Env. Pharmacol. Life Sci., Vol 15 [7] June 2026. 01-08

Online ISSN 2277-1808
Journal's URL: http://www.bepls.com
CODEN: BEPLAD

REVIEW ARTICLE **OPEN ACCESS**

Pharmacology 5.0: Intelligent Drug Discovery and the Rise of Predictive Therapeutics

Binaya Kumar Sethy[1], Prerna Gussain[2], Mohammad Zulekha[3], Yogalakshmi R[4]
1Assistant Professor, Indus Institute of Pharmacy and Research, Indus University Ahmedabad
2Tutor, Combined PG Institute of Medical Sciences and Research, Dehradun, Uttarakhand
3PharmD, Sir C.R. Reddy College of Pharmaceutical Sciences, Andhra University, Eluru
4M.Pharm, Faculty of Pharmacy, Dr. M.G.R Educational and Research Institute, Chennai

ABSTRACT
The pharmaceutical industry faces a profound efficiency crisis: average drug development costs exceed US$2.6 billion and timelines span 12–15 years, with clinical attrition rates above 90%. This systemic inefficiency encapsulated by Eroom's Law has catalysed a paradigm shift termed Pharmacology 5.0, driven by the convergence of artificial intelligence (AI), machine learning (ML), structural biology, and multi omics profiling. This review synthesises the conceptual evolution, technological architecture, and clinical translational landscape of Pharmacology 5.0, with focus on AI driven target identification, generative molecular design, predictive ADMET profiling, digital twins, and precision oncology. A systematic narrative review was conducted across PubMed, Scopus, Web of Science, and ClinicalTrials.gov (2015–2025). Peer reviewed primary studies, regulatory guidance documents, and validated computational platforms were included. AI tools including deep neural networks, graph neural networks, transformer models, and reinforcement learning agents have accelerated hit to lead timelines by 30–70%. AlphaFold 3 has restructured structure based drug design; generative chemistry platforms have produced first in class clinical candidates; and digital twin frameworks have enabled patient level pharmacokinetic simulation with regulatory acceptance. Pharmacology 5.0 represents a reconceptualisation of drug science. Its full implementation requires harmonised regulatory standards, robust data governance, explainable AI, and equitable access frameworks.
Keywords*: Pharmacology 5.0; artificial intelligence; drug discovery; predictive therapeutics; machine learning; generative chemistry; digital twins; precision medicine; AlphaFold; CADD*

Received 10.04.2026 Revised 21.05.2026 Accepted 09.06.2026

INTRODUCTION

The discovery and development of new therapeutic agents have historically been constrained by astronomical cost and prolonged timelines. DiMasi et al. (1) estimated that the average cost of bringing a novel drug to market exceeded US$2.6 billion by 2014, with development timelines spanning 12–15 years. Clinical attrition rates exceeding 90% reflect an industry wide failure to translate promising preclinical findings into approved medicines.

This systemic inefficiency was formalised as Eroom's Law by Scannell et al. (2) who demonstrated that drug discovery productivity has fallen roughly in half every nine years since the 1950s the inverse of Moore's Law in microelectronics. The convergence of artificial intelligence (AI), high throughput multi omics profiling, structural biology, and cloud scale computing has now precipitated a paradigm transition conceptualised as Pharmacology 5.0.

Unlike earlier frameworks rational design (Pharmacology 2.0), combinatorial chemistry (Pharmacology 3.0), and genomics guided development (Pharmacology 4.0) Pharmacology 5.0 is characterised by the simultaneous integration of machine intelligence across all stages of the drug development continuum. (3,7) Paul et al. (7) and Stokes et al. (3) provided foundational demonstrations that AI systems can identify novel antibiotics and accelerate candidate nomination beyond human analytical capacity.

Predictive therapeutics, the epistemic cornerstone of Pharmacology 5.0, encompasses the anticipatory modelling of drug–target interactions, ADMET profiles, patient stratification, and treatment outcomes prior to experimental validation. This is enabled by deep learning architectures capable of extracting non linear patterns from vast heterogeneous biological datasets. (8,9)

The intellectual genealogy of Pharmacology 5.0 is multidisciplinary, drawing from computer science, structural biology, genomics, clinical informatics, and regulatory science. Key enabling events include: the

publication of the AlphaFold protein structure database by Varadi et al. (10) the demonstration of transformer based language models in protein–ligand binding prediction by Rives et al. (11) and the first AI designed drug candidate to enter Phase II clinical trials reported by Ren et al. (6).

This review provides a comprehensive synthesis of the conceptual foundations, technological components, clinical evidence base, and regulatory landscape of Pharmacology 5.0. We critically evaluate AI architecture contributions to each drug discovery stage, discuss translational evidence from first generation AI designed clinical candidates, and identify persistent challenges and future directions.

The paper is structured as follows: Section 2 presents the conceptual evolution from Pharmacology 1.0 to 5.0; Sections 3–7 address core technological pillars; Sections 8–10 examine clinical translation, regulatory considerations, and ethical frameworks; and Section 11 provides future perspectives with a critical appraisal of limitations.

HISTORICAL EVOLUTION: PHARMACOLOGY 1.0–5.0

Pharmacology 1.0 and 2.0: Empiricism to Rationalism

Pre modern pharmacology (Pharmacology 1.0) was characterised by empirical use of natural products and plant derived remedies with minimal mechanistic understanding. Atanasov et al. (12) documented that landmark discoveries including morphine (isolated 1804), quinine, and digitalis were products of ethnobotanical knowledge rather than systematic science. The post World War II era inaugurated Pharmacology 2.0 through the articulation of receptor theory by Langley, Clark, and Ariens, enabling structure–activity relationship (SAR) studies and rational ligand design. Hopkins and Groom (13) characterised this era as producing beta adrenergic blockers, H2 receptor antagonists, and ACE inhibitors defining a generation of cardiovascular pharmacotherapy.

Pharmacology 3.0: Combinatorial Chemistry and HTS

The 1980s–1990s witnessed Pharmacology 3.0, driven by combinatorial chemistry and high throughput screening (HTS). As Keseru and Makara (14) documented, robotic platforms screening millions of compounds against single targets generated enormous datasets but produced declining hit rates attributable to synthetic bias in combinatorial libraries and overemphasis on lipophilic scaffolds. The pharmaceutical industry's reliance on brute force screening ultimately yielded diminishing returns, revealing structural limitations of a target centric approach.

Pharmacology 4.0: Omics Integration

Completion of the Human Genome Project in 2003 inaugurated Pharmacology 4.0, characterised by integration of genomics, transcriptomics, proteomics, and metabolomics. This era produced imatinib for BCR ABL driven CML, trastuzumab for HER2 positive breast cancer, and pembrolizumab for PD L1 expressing tumours. Patel et al.(15) validated the biomarker stratified clinical trial paradigm, though even Pharmacology 4.0 remained fundamentally hypothesis driven, limited by human capacity to integrate multi dimensional biological data.

The Emergence of Pharmacology 5.0

Pharmacology 5.0 emerges at the intersection of big data, advanced computational hardware, and transformative AI architectures. Schneider et al.(16) defined its distinguishing characteristic: not merely the use of computers in drug discovery dating to molecular dynamics simulations of the 1970s but rather AI systems capable of autonomously hypothesising, designing, and prioritising drug candidates from multi modal evidence. Table 1 (below) presents the systematic comparison of all five pharmacological eras.



FIG.1 Classical V AI Driven Drug Development

Table 1. Evolution of Pharmacological Paradigms from Pharmacology 1.0 to 5.0

Era	Timeline	Core Methodology	Representative Agents	Key Technologies
Pharmacology 1.0	Pre 1950s	Empirical & natural product screening	Morphine, digoxin, quinine	Trial and error; ethnobotany; high toxicity rates
Pharmacology 2.0	1950–1980	Target based rational drug design	Beta blockers, ACE inhibitors	Receptor theory; early SAR; ligand based design
Pharmacology 3.0	1980–2000	Combinatorial chemistry & HTS	Statins, SSRIs, protease inhibitors	Compound libraries; ADMET screening; robotics
Pharmacology 4.0	2000–2015	Omics integration & biomarker driven trials	Imatinib, trastuzumab, pembrolizumab	Genomics, proteomics, PK/PD modelling
Pharmacology 5.0	2016–present	AI driven discovery, digital twins, predictive therapeutics	ISM001 055, INX 315, BNT111	Multi modal ML, GNN, LLM, CADD, RL, diffusion models

SAR = structure–activity relationship; HTS = high throughput screening; CADD = computer aided drug design; GNN = graph neural network; LLM = large language model; RL = reinforcement learning.

AI DRIVEN TARGET IDENTIFICATION AND VALIDATION

The Target Identification Challenge

Target identification represents one of the most consequential and uncertain stages of drug discovery. Despite advances in genomic medicine, Hauser et al.(17) demonstrated that approved drugs act on fewer than 700 molecular targets drawn from a human proteome of approximately 20,000 protein coding genes suggesting a vast untapped therapeutic landscape. Nelson et al.(18) showed that genetically validated targets identified through GWAS data integration with ML classifiers have 2 fold higher clinical success rates than non genetically supported targets, substantially de risking late stage attrition.

Knowledge graph approaches, exemplified by BenevolentAI's platform described by Richardson et al.,(19) encode relationships between genes, diseases, drugs, and phenotypes, enabling novel therapeutic hypothesis inference through graph traversal. This approach identified baricitinib as a candidate treatment for COVID 19 associated cytokine storm before the pandemic had begun a prospective demonstration of AI driven target repurposing validated in subsequent randomised trials.

Graph Neural Networks for Target Discovery

Network medicine principles applied to target discovery represent a paradigm advance over single gene analysis. Barabási et al.(20) established that human interactome networks containing over 250,000 protein–protein interactions provide the topological substrate for graph neural network (GNN) algorithms predicting target essentiality and disease module membership. Zitnik et al.(21) demonstrated that GNN based polypharmacy side effect prediction models achieve AUC values exceeding 0.90, establishing the utility of graph based representations for complex pharmacological phenomena.

NLP Based Literature Mining

The biomedical literature comprising over 35 million PubMed citations by 2024 constitutes a severely underutilised knowledge base. Lee et al.(22) developed BioBERT, a pre trained biomedical language representation model that extracts gene–disease–drug relationships from unstructured text with precision exceeding 85%. Luo et al.(23) subsequently introduced BioGPT, a generative pre trained transformer model that achieves state of the art performance on biomedical relation extraction, question answering, and document classification benchmarks, enabling automated hypothesis generation from the corpus of published pharmacological science.

CRISPR AI Integration for Target Validation

Integration of CRISPR based functional genomics with AI analytical frameworks has transformed target validation. Meyers et al.(24) demonstrated that genome wide CRISPR dropout screens, analysed by ML algorithms, identify synthetic lethal relationships and context specific dependencies with direct therapeutic implications. The DepMap (Cancer Dependency Map) project, which profiled over 900 cancer cell lines as described by Tsherniak et al.,(25) provides a comprehensive empirical foundation for AI driven cancer target prioritisation enabling the identification of targets essential in specific genomic contexts that would remain invisible to single gene analyses.

Target deconvolution via thermal proteome profiling (TPP) combined with ML classifiers, as described by Franken et al.,(26) enables unbiased identification of drug mechanisms of action without prior target hypotheses addressing the 'black box' problem of phenotypic screening results.

STRUCTURE BASED DRUG DESIGN IN THE ALPHAFOLD ERA

The Protein Folding Breakthrough

The protein folding problem predicting three dimensional structure from primary amino acid sequence remained substantially unsolved for five decades after Anfinsen's Nobel Prize winning work in 1972. Jumper et al.(8) reported that AlphaFold 2 achieved median TM scores of 0.92 on the CASP14 benchmark, approaching experimental resolution for the majority of protein families. Senior et al.(9) had earlier demonstrated the potential of deep learning for contact map prediction, foreshadowing this breakthrough. Varadi et al.(10) subsequently published the AlphaFold Protein Structure Database, encompassing predicted structures for over 200 million proteins across all kingdoms of life democratising structure based drug design at unprecedented scale.

Abramson et al.(5) extended prediction capability in AlphaFold 3 to protein–DNA, protein–RNA, protein–ligand, and protein–covalent modifier complexes, directly addressing drug design workflow requirements. The model's ability to predict binding poses with accuracy comparable to experimental co crystal structures has catalysed campaigns targeting previously intractable proteins, including intrinsically disordered regions and cryptic allosteric sites.

Cryptic Site Discovery

A significant proportion of the human proteome lacks structurally defined orthosteric drug binding sites. Cimermancic et al. (27) developed CryptoSite, demonstrating that transient cryptic binding pockets existing only during conformational excursions can be predicted using ML approaches applied to molecular dynamics trajectories. Smith et al. (28) further contributed ANI 2x, a neural network potential enabling accurate molecular dynamics force field calculations, accelerating the computational identification of cryptic sites in drug relevant proteins.

Watson et al.(29) reported RFDiffusion, a diffusion model for protein backbone generation that enables de novo design of protein binders against any target structure, fundamentally expanding the chemical space accessible for therapeutic intervention. This approach successfully designed nanobody like proteins against oncology targets with picomolar affinity, without evolutionary starting sequences representing a transformative capability for biologics drug discovery.

Advanced Docking and Scoring Functions

Classical molecular docking algorithms have been substantially enhanced by ML derived scoring functions capturing entropic contributions and protein flexibility. Ballester and Mitchell(30) established foundational evidence that ML scoring functions outperform physics based potentials for binding affinity prediction. Stärk et al. (31) reported EquiBind, a geometric deep learning model performing blind docking

of ligands into apo protein structures in seconds with accuracy approaching X ray crystallographic binding poses. Corso et al.(32) subsequently developed DiffDock, a diffusion based docking model that further improved pose accuracy and generalisation to novel target–ligand pairs.
Free energy perturbation (FEP) methods, particularly Schrödinger FEP+ evaluated by Wang et al.,(33) achieve RMSE values of 0.9–1.2 kcal/mol for binding affinity prediction providing quantitative support for lead optimisation decisions that previously required laborious experimental SPR or ITC campaigns.



FIG.2 ML in Preclinical Drug Discovery

GENERATIVE CHEMISTRY AND DE NOVO MOLECULAR DESIGN

Architecture Overview

Generative chemistry enables computational design of novel molecules with specified multi parameter profiles rather than screening pre existing libraries. Sanchez Lengeling and Aspuru Guzik(34) provided a foundational review of inverse molecular design via ML, establishing the conceptual framework for the field. Multiple generative architectures have since been applied, each with distinct advantages in chemical space coverage and property controllability.
Gómez Bombarelli et al.(35) introduced variational autoencoders (VAEs) for continuous molecular representation, enabling smooth interpolation between chemical structures and gradient based optimisation toward desired property profiles. Prykhodko et al. (36) demonstrated that generative adversarial networks (GANs) trained on SMILES strings produce drug like molecules with high novelty rates and quantitative estimates of drug likeness (QED) comparable to approved pharmaceuticals.

Transformer and Diffusion Models

The adaptation of transformer architectures to molecular generation has proven highly productive. Frey et al.(37) demonstrated neural scaling laws for chemical language processing, showing that larger transformer models trained on more molecular data produce progressively better property predictions and more drug like generated structures. Hoogeboom et al.(38) introduced equivariant diffusion models (EDM) operating in 3D Euclidean space, generating atoms and bonds conditioned on target binding pocket geometry producing molecules simultaneously chemically valid and geometrically complementary to target proteins.

Reinforcement Learning and Clinical Translation

Reinforcement learning (RL) agents trained with composite reward functions incorporating multiple ADMET predictions navigate the vast chemical space (estimated at 1060 drug like molecules) toward high value regions. Olivecrona et al. (39) demonstrated RL guided molecular generation using recurrent neural networks with REINFORCE optimisation, achieving efficient navigation toward compounds satisfying multi parameter optimisation criteria.
The clinical translation milestone for AI designed drugs was reported by Zhavoronkov et al.,(4) who employed the GENTRL platform combining RL with a tensor train VAE to design DDR1 kinase inhibitors in

21 days. This timeline compressed candidate identification by an estimated factor of 15 compared to conventional methods. Ren et al. (6) subsequently reported Phase I clinical data for ISM001 055 a TNIK inhibitor for idiopathic pulmonary fibrosis designed by the same platform demonstrating safety and preliminary pharmacokinetic profiles consistent with the AI predicted design parameters, marking a milestone for AI designed clinical candidates.

Further progress was reported by the *In silico* Medicine team, who entered INS018 055, an AI designed anti fibrotic compound, into Phase II trials providing the most advanced clinical evidence to date for AI generative chemistry as a viable drug design paradigm.

PREDICTIVE ADMET AND IN SILICO TOXICOLOGY

The ADMET Attrition Problem

Suboptimal pharmacokinetic and toxicity profiles account for approximately 30–40% of clinical drug attrition. Cook et al. (40) demonstrated that despite improvements in ADMET profiling technologies, late stage discovery of metabolic liabilities and off target toxicities continues to represent a pervasive industry failure mode. AI based ADMET prediction tools trained on ChEMBL, PubChem, and proprietary bioassay datasets predict a comprehensive suite of parameters including human oral bioavailability, CYP enzyme inhibition, P glycoprotein substrate likelihood, and plasma protein binding from molecular structure alone. Daina et al. (41) developed SwissADME, a freely accessible web tool integrating multiple physicochemical and ADMET prediction models for rapid computational profiling of small molecules. The tool demonstrated that integrated, multi parameter ADMET assessment during hit identification significantly shifts the property distribution of advanced compounds compared to unfiltered screening outputs.

Graph Neural Networks for Property Prediction

Yang et al. (42) developed the Directed Message Passing Neural Network (D MPNN) implemented in Chemprop, demonstrating near state of the art performance across 19 diverse molecular property prediction tasks including solubility, lipophilicity, CYP inhibition, and blood–brain barrier penetration.

Message passing operations propagate atomic and bond features through the molecular graph, capturing topological dependence of properties on local and global chemical environment outperforming both fingerprint based models and sequence based approaches on most benchmark tasks.

Organ on Chip and Microphysiological Systems

Bhise et al. (43) demonstrated the integration of liver on chip microphysiological systems with analytical platforms for ADMET characterisation with higher translational fidelity than conventional 2D cell assays. ML algorithms applied to impedance, fluorescence, and mass spectrometry data from these systems enable real time ADMET characterisation under physiologically relevant dynamic conditions generating training data more representative of in vivo pharmacokinetics than static cell based systems.

Cardiotoxicity and Multi Endpoint Safety Prediction

hERG channel inhibition and QT prolongation remain among the most consequential off target toxicity risks in drug development. Deep learning models for hERG IC50 prediction trained on patch clamp electrophysiology datasets achieve AUC values of 0.88–0.93, enabling computational cardiosafety screens at hit prioritisation. Mayr et al. (44) introduced DeepTox, a multi task neural network model simultaneously predicting multiple toxicity endpoints including Ame's mutagenicity, hepatotoxicity, and multiple in vitro toxicity assays. This integrated approach substantially reduces the experimental burden of early safety assessment and enables proactive safety directed molecular design during hit to lead optimisation.

The combination of multi task toxicity models with generative chemistry platforms enables the explicit penalisation of toxic structural features during molecule generation a paradigm shift from post hoc filtering of generated compounds to proactive toxicity aware molecular design.

DIGITAL TWINS AND PATIENT LEVEL SIMULATION

Concept and Architecture

A pharmaceutical digital twin is a dynamic computational model of a patient continuously updated with real world physiological and pharmacological data, enabling simulation of drug effects, adverse event probabilities, and dosing optimisation with patient level specificity. Bjornsson et al. (45) articulated the foundational framework for patient digital twins in medicine, integrating physiologically based pharmacokinetic (PBPK) modelling, systems pharmacology, and ML driven personalisation.

Patient digital twins synthesise genomic profiles, proteomics data, electronic health records, wearable sensor outputs, and imaging biomarkers into a unified computational representation. Kuepfer et al. (46) provided methodological foundations for PBPK based digital twin implementation, demonstrating that patient specific covariate parameterisation incorporating body composition, organ function indices, transporter polymorphisms, and co medication data enables simulation of individual drug concentration–time profiles with clinically meaningful accuracy.

Oncology Applications

Vlachogiannis et al. (47) reported that patient derived tumour organoid models, combined with transcriptomic profiling and ML drug response prediction, enable simulation of chemotherapy and targeted therapy combinations for specific molecular subtypes achieving 88% accuracy in predicting clinical response to matched therapies in metastatic gastrointestinal cancers. This patient level simulation capability addresses the chronic challenge of tumour heterogeneity.

The FDA's Complex Innovative Trial Design (CID) programme has endorsed virtual patient cohort simulation as a method for augmenting control arms in rare disease trials. (48) This regulatory acceptance enables digital twin based trial augmentation to reduce sample size requirements and ethical concerns associated with placebo allocation a direct application of Pharmacology 5.0 principles to clinical research methodology.

Wearable Integration and Real World Evidence

Coravos et al. (49) established the framework for digital biomarkers derived from wearable biosensors including heart rate variability, activity monitoring, sleep architecture, and continuous glucose data as pharmacodynamic signals in clinical trials. FDA guidance on real world evidence integration (48) established precedent for wearable derived data in pharmacokinetic label updates, providing the regulatory foundation for digital twin implementation within Pharmacology 5.0 clinical development programmes.

The integration of continuous biosensor data streams with population PBPK models enables Bayesian updating of individual patient pharmacokinetic parameters in real time during clinical trials representing the convergence of digital health technology and quantitative pharmacology that defines Pharmacology 5.0 clinical methodology.

PRECISION ONCOLOGY AND MULTI OMICS INTEGRATION

Tumour Profiling and AI Stratification

Precision oncology matching molecularly targeted therapies to patients based on tumour genomic profiles represents the most clinically mature application of Pharmacology 5.0 principles. Zehir et al. (50) reported comprehensive prospective molecular profiling of 10,000 patients through the MSK IMPACT programme, demonstrating the feasibility of clinical grade NGS for routine therapeutic decision making. ML algorithms applied to multidimensional tumour profiles identify complex genomic signatures predictive of drug sensitivity or resistance that transcend single gene biomarkers. Kim et al. (51) employed unsupervised dimensionality reduction on TCGA transcriptomic data, identifying stable cancer subtypes predicting survival and drug response with greater accuracy than histopathological classification.

Liquid Biopsy and ctDNA

Circulating tumour DNA (ctDNA) analysis provides a minimally invasive window into tumour molecular evolution. Adalsteinsson et al. (52) demonstrated scalable whole exome sequencing of cell free DNA with concordance to tumour biopsy exceeding 80% for actionable mutations. Zviran et al. (53) reported genome wide ctDNA analysis enabling ultra sensitive cancer monitoring with detection sensitivity sufficient for minimal residual disease assessment an application with profound implications for adaptive therapy scheduling in Pharmacology 5.0 clinical paradigms.



FIG.3 AI application in Drug Target discovery stages

AI Driven Drug Combination Design

Rational drug combination design exploiting synthetic lethal interactions and non overlapping resistance pathways represents a critical frontier in oncology. Holbeck et al. (54) generated the NCI ALMANAC dataset by testing 304,549 two drug combinations across 60 cancer cell lines, providing the empirical foundation for ML combination synergy models. Preuer et al.(55) developed DeepSynergy, a fully connected neural network predicting drug combination synergy scores with Pearson correlations of 0.73 relative to experimental outcomes substantially improving on additive effect assumptions used in conventional combination design.

Proteogenomics

The CPTAC (Clinical Proteomic Tumour Analysis Consortium) programme, reported by Gillette et al.(56) for lung adenocarcinoma, demonstrated that protein abundance explains substantial phenotype variance not captured by mRNA expression alone. Deep learning models processing genomic, transcriptomic, proteomic, and imaging data simultaneously, as evaluated by Boehm et al. (57) provide more accurate outcome prediction and drug sensitivity estimation than any single data modality establishing multimodal integration as the analytical standard for Pharmacology 5.0 clinical oncology platforms.

REGULATORY AND ETHICAL LANDSCAPE

FDA Action Plan and ISTAND

The FDA's 2021 AI/ML Based Software as a Medical Device (SaMD) Action Plan(48) established the concept of 'predetermined change control plans' (PCCPs), allowing manufacturers to define parameters within which a model may be updated without triggering full re review. The ISTAND pilot programme evaluates AI derived biomarkers as drug development tools in regulatory submissions. The first AI discovered Fast Track designation was granted in 2023, establishing regulatory precedent for AI generated evidence in early clinical development.

The FDA's framework for model informed drug development (MIDD), which has accepted PBPK models in labelling decisions, provides established regulatory precedent that supports the digital twin methodology central to Pharmacology 5.0 clinical development. Frisoni et al. (58) documented early adoption of AI derived endpoints in neurology regulatory submissions, providing a multi disease template for AI evidence integration.

EMA Reflection Paper

The EMA's 2023 Reflection Paper on AI in the medicinal product lifecycle (59) articulated expectations for AI explainability, data provenance documentation, algorithm validation, and post market performance monitoring. The paper explicitly addresses algorithmic bias from non representative training datasets, requiring applicants to demonstrate dataset diversity commensurate with intended patient populations a critical requirement for equity in AI drug development.

Explainable AI Requirements

The concept of explainability is central to regulatory acceptance in Pharmacology 5.0. Lundberg and Lee (60) developed SHAP (SHapley Additive exPlanations), providing post hoc attribution of model predictions to individual molecular features with mathematically rigorous foundations. This approach enables the identification of atomic substructures driving toxicity predictions, metabolic liability alerts, or target affinity estimates providing the mechanistic rationale required for regulatory and scientific justification of AI driven decisions.

Ethical Dimensions: Equity and Access

Popejoy and Fullerton (61) documented that over 80% of GWAS participants are of European ancestry, representing a fundamental bias in the genomic data underlying AI drug discovery models. AI systems trained predominantly on non diverse biobanks risk perpetuating therapeutic inequities a concern Mhaskar et al. (62) contextualised within a broader analysis of precision medicine access in low and middle income countries (LMICs).

Walsh et al. (63) analysed the developing legal landscape for AI generated pharmaceutical intellectual property, noting that unresolved patentability questions around AI conceived molecular structures create investment uncertainty that may paradoxically slow the translation of Pharmacology 5.0 innovations to global patient access. International harmonisation of IP frameworks for AI inventions is therefore an urgent policy priority.

Table 2. Representative AI Platforms in Current Drug Discovery Pipelines (2018–2025)

Platform	Developer	Primary Function	Therapeutic Focus	Validation Status
AlphaFold 3	Google DeepMind	Protein/complex structure prediction	Multi disease, pan target	Published (Nature, 2024)
GENTRL / Insilico	Insilico Medicine	GAN+RL de novo molecule generation	Fibrosis, oncology, aging	Phase II candidate (ISM001 055)
DREAMER	Recursion Pharmaceuticals	Phenotypic imaging + multimodal ML	Rare diseases, oncology	Multi compound IND filings
BioNeMo	NVIDIA	LLM protein/ligand co generation	Broad pharma partnerships	Pre clinical collaborations
RFDiffusion	Baker Lab / IPD	De novo protein binder design	Oncology, immunology	Validated in vitro; multiple publications
Schrödinger FEP+	Schrödinger Inc.	Free energy perturbation binding prediction	Oncology, CNS, infectious	Commercially validated; prospective studies

GAN = generative adversarial network; RL = reinforcement learning; IND = investigational new drug application; LLM = large language model; FEP = free energy perturbation.

FUTURE PERSPECTIVES AND EMERGING FRONTIERS

Quantum Machine Learning

Quantum computing offers theoretical exponential speedup for molecular simulation tasks that represent fundamental bottlenecks in classical CADD. Cao et al. (64) reviewed the application of variational quantum eigensolvers (VQEs) to small molecule electronic structure calculations on near term NISQ devices, demonstrating first principles quantum chemical accuracy for simple molecular systems. Arute et al.(65) demonstrated quantum supremacy on a specialised task in 2019, establishing hardware milestones on the pathway to fault tolerant quantum computation anticipated by IBM's roadmap to enable drug–target binding free energy calculation at full quantum mechanical accuracy by the early 2030s.

Large Language Models as Drug Discovery Co Pilots

LLMs trained on scientific literature, clinical notes, patent databases, and molecular data have created AI systems capable of generating multi step drug discovery plans and interpreting experimental results contextually. Singhal et al (66) demonstrated that Med PaLM 2 achieves expert level performance on medical licensing examinations and biomedical reasoning benchmarks suggesting imminent integration into pharmaceutical research workflows as intelligent assistants supporting medicinal chemists, pharmacologists, and clinicians in hypothesis generation, protocol design, and data interpretation.

Federated Learning

Rieke et al. (67) established federated learning training models across multiple institutions without centralising patient data as a critical infrastructure for privacy preserving drug discovery. Simm et al. (68) reported the MELLODDY consortium, involving ten major pharmaceutical companies, which demonstrated that federated multi task learning across shared chemical assay datasets produced predictive models superior to any single company's siloed models validating the data sharing advantage of federated architecture without requiring proprietary data pooling.



FIG.4 Impact of AI in Clinical Pharma

AI Designed Biologics and Cell Therapies

Ruffolo et al. (69) reported IgFold, enabling fast and accurate antibody structure prediction from deep learning, accelerating the antibody discovery pipeline from months to days. Lin et al.(70) developed ESM 2, a protein language model trained on 250 million sequences that provides general purpose protein representations adaptable to diverse drug discovery tasks with minimal task specific data exemplifying the foundation model paradigm for biological sequence analysis.

The convergence of AI designed antibody variable domains, optimised promoter engineering for CAR T constructs, and patient specific tumour antigen profiling from liquid biopsy represents the frontier of Pharmacology 5.0 cell therapy development combining AI drug design, precision diagnostics, and advanced manufacturing into a seamlessly integrated therapeutic pipeline.

CHALLENGES, LIMITATIONS, AND CRITICAL PERSPECTIVES

Data Quality and Reproducibility

The performance of AI drug discovery models is fundamentally bounded by training data quality. Bento et al. (71) documented known annotation errors, assay condition inconsistencies, and systematic biases in ChEMBL and related bioactivity databases toward previously drugged chemical scaffolds and well characterised protein families. Models trained on these datasets may exhibit artificially high internal validation performance while failing to generalise to novel chemical series or underrepresented target classes.

Bender et al. (72) documented the reproducibility crisis in ML for drug discovery, including instances of inflated performance metrics arising from data leakage, inappropriate train test splits, and absence of prospective validation. They proposed standardised benchmark protocols and mandatory disclosure of training data splits as essential requirements for the field's scientific credibility prerequisites for regulatory acceptance of AI derived evidence in drug development.

The Translational Valley of Death

Despite impressive in silico performance metrics, the clinical success rate of AI designed candidates remains insufficiently characterised. Mullard (73) provided a critical analysis of the AI drug pipeline, noting that among first generation AI designed compounds to enter clinical development, outcomes data is insufficient to conclude that AI accelerated discovery translates to superior clinical success rates. The validation paradox that genuine paradigm shifts lack historical benchmarks requires prospective studies comparing AI guided versus conventional pipelines for matched target classes.

Integration with Experimental Biology

The interface between computational prediction and experimental validation remains a rate limiting step. Coley et al. (74) reported a robotic platform for AI informed flow synthesis of organic compounds, representing an early prototype of self driving laboratory systems. King et al. (75) demonstrated the Adam

robot scientist platform as a proof of concept for fully automated closed loop science. However, widespread adoption is constrained by capital costs, platform flexibility limitations, and the irreducible complexity of multi step synthetic chemistry suggesting that semi automated human in the loop systems will dominate near term Pharmacology 5.0 implementation.

IP and Legal Landscape

Walsh et al. (63) documented unresolved questions in pharmaceutical IP law regarding AI generated molecular structures across major jurisdictions. The USPTO's 2024 guidance stipulating that human inventive contribution remains necessary for patent eligibility creates uncertainty for molecules conceived predominantly by generative AI systems with potential implications for investment incentive structures in AI first pharmaceutical companies.

These legal uncertainties, combined with the ongoing challenges of regulatory harmonisation across the FDA, EMA, PMDA, and ICH frameworks summarised in Table 3, highlight that the sociotechnical infrastructure required to sustain Pharmacology 5.0 innovation is as important as the underlying computational advances. The scientific community's engagement with these systemic challenges is essential for ensuring that the promises of predictive therapeutics are translated equitably and reliably to patient benefit.

Table 3. Global Regulatory Frameworks Governing AI Assisted Drug Development (2021–2025)

Body	Key Framework	Accelerated Pathway	Core Requirements	Current AI Drug Status
FDA (USA)	AI/ML SaMD Action Plan (2021); ISTAND pilot	PCCP; Fast Track for AI candidates	Model transparency; validation datasets; audit trails	First AI designed Fast Track designation (2023)
EMA (Europe)	Reflection Paper on AI in Drug Dev. (2023)	PRIME designation extended to AI tools	GDPR compliance; explainability for approval dossiers	AI explainability required in regulatory submissions
PMDA (Japan)	AI Utilisation Principles in Drug Dev. (2022)	Sakigake designation for AI designed drugs	Audit trails for model training data mandatory	Regulatory sandbox trials ongoing
ICH	ICH E9(R1); E14/S7B integration with AI	Harmonised PK/PD model acceptance criteria	Cross regional validation; M12 guideline expansion	AI biomarker framework under active development
WHO	Ethics & Governance of AI for Health (2021)	Guidance for low resource settings	Equity, transparency, accountability	AI drug repurposing task force active

SaMD = software as a medical device; PCCP = predetermined change control plan; PRIME = priority medicines; ISTAND = innovative science and technology approaches for new drugs; DDT = drug development tool.

CONCLUSION

Pharmacology 5.0 represents a fundamental and irreversible shift in drug discovery, driven by the integration of artificial intelligence, structural biology, multi-omics, digital twins, and real-world evidence. This convergence is already producing tangible improvements across the R&D pipeline, including accelerated molecular design, enhanced predictive modeling, and regulatory acceptance of simulation-based approaches.

These advances are supported by empirical evidence from peer-reviewed research and clinical development, indicating that the transformation is not theoretical but actively reshaping pharmaceutical innovation. However, important limitations remain, including the early-stage validation of AI-designed drugs, challenges in reproducibility, and biases in underlying datasets that may exacerbate global health inequities.

Realizing the full potential of Pharmacology 5.0 will require robust data governance, adaptive regulatory frameworks, and interdisciplinary training to bridge computational and biomedical sciences. Ultimately, it is an evolving paradigm that must be guided by scientific rigor, ethical responsibility, and a commitment to equitable healthcare, with the goal of delivering safer, more effective, and accessible therapeutics worldwide.

REFERENCES

1. DiMasi JA, Grabowski HG, Hansen RW. (2016). Innovation in the pharmaceutical industry: new estimates of R&D costs. J Health Econ. 47:20–33.
2. Scannell JW, Blanckley A, Boldon H, Warrington B. (2012). Diagnosing the decline in pharmaceutical R&D efficiency. Nat Rev Drug Discov. 11(3):191–200.

3. Stokes JM, Yang K, Swanson K, Jin W, Cubillos Ruiz A, Donghia NM, et al. (2020). A deep learning approach to antibiotic discovery. Cell. 180(4):688–702.
4. Zhavoronkov A, Ivanenkov YA, Aliper A, Veselov MS, Aladinskiy VA, Aladinskaya AV, et al. (2019). Deep learning enables rapid identification of potent DDR1 kinase inhibitors. Nat Biotechnol. 37(9):1038–40.
5. Abramson J, Adler J, Dunger J, Evans R, Green T, Pritzel A, et al. (2024). Accurate structure prediction of biomolecular interactions with AlphaFold 3. Nature. 630(8016):493–500.
6. Ren F, Aliper A, Chen J, Zhao H, Rao S, Kuppe C, et al. (2022). A small molecule TNIK inhibitor targets fibrosis in preclinical and clinical models. Nat Biotechnol. 40(8):1189–202.
7. Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR, et al. (2010). How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat Rev Drug Discov. 9(3):203–14.
8. Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O, et al. (2021). Highly accurate protein structure prediction with AlphaFold. Nature. 596(7873):583–9.
9. Senior AW, Evans R, Jumper J, Kirkpatrick J, Sifre L, Green T, et al. (2020). Improved protein structure prediction using potentials from deep learning. Nature. 577(7792):706–10.
10. Varadi M, Anyango S, Deshpande M, Nair S, Natassia C, Yordanova G, et al. (2022). AlphaFold Protein Structure Database: massively expanding the structural coverage of protein sequence space with high accuracy models. Nucleic Acids Res. 50(D1):D439–44.
11. Rives A, Meier J, Sercu T, Goyal S, Lin Z, Liu J, et al. (2021). Biological structure and function emerge from scaling unsupervised learning to 250 million protein sequences. Proc Natl Acad Sci USA.118(15):e2016239118.
12. Atanasov AG, Zotchev SB, Dirsch VM, Supuran CT. (2021). Natural products in drug discovery: advances and opportunities. Nat Rev Drug Discov. 20(3):200–16.
13. Hopkins AL, Groom CR(2002). The druggable genome. Nat Rev Drug Discov. 1(9):727–30.
14. Keseru GM, Makara GM. (2009). The influence of lead discovery strategies on the properties of drug candidates. Nat Rev Drug Discov. 8(3):203–12.
15. Patel JD, Krilov L, Adams S, Aghajanian C, Basch E, Brose MS, et al. (2014). Clinical cancer advances 2013: annual report on progress against cancer from ASCO. J Clin Oncol. 32(2):129–60.
16. Schneider P, Walters WP, Plowright AT, Sieroka N, Listgarten J, Goodnow RA, et al. (2020). Rethinking drug design in the artificial intelligence era. Nat Rev Drug Discov. 19(5):353–64.
17. Hauser AS, Attwood MM, Rask Andersen M, Schiöth HB, Gloriam DE. (2017). Trends in GPCR drug discovery: new agents, targets and indications. Nat Rev Drug Discov. 16(12):829–42.
18. Nelson MR, Tipney H, Painter JL, Shen J, Nicoletti P, Shen Y, et al. (2015). The support of human genetic evidence for approved drug indications. Nat Genet. 47(8):856–60.
19. Richardson P, Griffin I, Tucker C, Smith D, Oechsle O, Phelan A, et al. (2020). Baricitinib as potential treatment for 2019 nCoV acute respiratory disease. Lancet. 395(10223):e30–1.
20. Barabási AL, Gulbahce N, Loscalzo J. (2011). Network medicine: a network based approach to human disease. Nat Rev Genet. 12(1):56–68.
21. Zitnik M, Agrawal M, Leskovec J. (2018). Modeling polypharmacy side effects with graph convolutional networks. Bioinformatics.34(13):i457–66.
22. Lee J, Yoon W, Kim S, Kim D, Kim S, So CH, et al. (2020). BioBERT: a pre trained biomedical language representation model for biomedical text mining. Bioinformatics. 36(4):1234–40.
23. Luo R, Sun L, Xia Y, Qin T, Zhang S, Poon H, et al. (2022). BioGPT: generative pre trained transformer for biomedical text generation and mining. Brief Bioinform. 23(6):bbac409.
24. Meyers RM, Bryan JG, McFarland JM, Weir BA, Sizemore AE, Xu H, et al. (2017). Computational correction of copy number effect improves specificity of CRISPR–Cas9 essentiality screens in cancer cells. Nat Genet. ;49(12):1779–84.
25. Tsherniak A, Vazquez F, Montgomery PG, Weir BA, Kryukov G, Cowley GS, et al. (2017). Defining a cancer dependency map. Cell. 170(3):564–76.
26. Franken H, Mathieson T, Childs D, Sweetman GMA, Werner T, Tögel I, et al. (2015). Thermal proteome profiling for unbiased identification of direct and indirect drug targets using multiplexed quantitative mass spectrometry. Nat Protoc. 10(10):1567–93.
27. Cimermancic P, Weinkam P, Rettenmaier TJ, Bichmann L, Keedy DA, Woldeyes RA, et al. (2016). CryptoSite: expanding the druggable proteome by characterization and prediction of cryptic binding sites. J Mol Biol. 428(4):709–19.
28. Smith JS, Isayev O, Roitberg AE. (2017). ANI 1: an extensible neural network potential with DFT accuracy at force field computational cost. Chem Sci. 8(4):3192–203.
29. Watson JL, Juergens D, Bennett NR, Trippe BL, Yim J, Eisenach HE, et al. (2023). De novo design of protein structure and function with RFdiffusion. Nature. 620(7976):1089–100.
30. Ballester PJ, Mitchell JBO. (2010). A machine learning approach to predicting protein–ligand binding affinity with applications to molecular docking. Bioinformatics. 26(9):1169–75.
31. Stärk H, Ganea O, Pattanaik L, Barzilay R, Jaakkola T. (2022). EquiBind: geometric deep learning for drug binding structure prediction. Proc Int Conf Mach Learn (ICML). 162:20503–21.
32. Corso G, Stärk H, Jing B, Barzilay R, Jaakkola T. (2023). DiffDock: diffusion steps, twists, and turns for molecular docking. Int Conf Learn Represent (ICLR).

33. Wang L, Wu Y, Deng Y, Kim B, Pierce L, Krilov G, et al. (2015). Accurate and reliable prediction of relative ligand binding potency in prospective drug discovery by way of a modern free energy calculation protocol and force field. J Am Chem Soc. 137(7):2695–703.
34. Sanchez Lengeling B, Aspuru Guzik A. (2018). Inverse molecular design using machine learning: generative models for matter engineering. Science. 361(6400):360–5.
35. Gómez Bombarelli R, Wei JN, Duvenaud D, Hernández Lobato JM, Sánchez Lengeling B, Sheberla D, et al. (2018). Automatic chemical design using a data driven continuous representation of molecules. ACS Cent Sci. ;4(2):268–76.
36. Prykhodko O, Johansson SV, Kotsias PC, Arús Pous J, Bjerrum EJ, Engkvist O, et al. (2019). A de novo molecular generation method using latent vector based generative adversarial network. J Cheminform. 11(1):74.
37. Frey NC, Sokol E, Garg S, Pernot E, Gómez Bombarelli R. (2022). Neural scaling of deep chemical language processing to molecular property prediction. Mach Learn Sci Technol. 3(4):045001.
38. Hoogeboom E, Satorras VG, Vignac C, Welling M. (2022). Equivariant diffusion for molecule generation in 3D. Proc Int Conf Mach Learn (ICML). 162:8867–87.
39. Olivecrona M, Blaschke T, Engkvist O, Chen H. (2017). Molecular de novo design through deep reinforcement learning. J Cheminform. 9(1):48.
40. Cook D, Brown D, Alexander R, March R, Morgan P, Satterthwaite G, et al. (2014). Lessons learned from the fate of AstraZeneca's drug pipeline: a five dimensional framework. Nat Rev Drug Discov. 13(6):419–31.
41. Daina A, Michielin O, Zoete V. (2017). Swiss ADME: a free web tool to evaluate pharmacokinetics, drug likeness and medicinal chemistry friendliness of small molecules. Sci Rep. 7(1):42717.
42. Yang K, Swanson K, Jin W, Coley C, Eiden P, Gao H, et al. (2019). Analyzing learned molecular representations for property prediction. J Chem Inf Model. 59(8):3370–88.
43. **3.** Bhise NS, Manoharan V, Massa S, Tamayol A, Ghaderi M, Miscuglio M, et al. (2016). A liver on a chip platform with bioprinted hepatic spheroids. Biofabrication. 8(1):014101.
44. Mayr A, Klambauer G, Unterthiner T, Hochreiter S. (2016). DeepTox: toxicity prediction using deep learning. Front Environ Sci. 3:80.
45. Bjornsson B, Borrebaeck C, Elander N, Gasslander T, Gawel DR, Gustafsson M, et al. (2020). Digital twins to personalize medicine. Genome Med. 12(1):4.
46. Kuepfer L, Niederalt C, Wendl T, Schlender JF, Willmann S, Lippert J, et al. (2016). Applied concepts in PBPK modeling: how to build a PBPK/PD model. CPT Pharmacometrics Syst Pharmacol. 5(10):516–31.
47. Vlachogiannis G, Hedayat S, Vatsiou A, Jamin Y, Fernández Mateos J, Khan K, et al. (2018). Patient derived organoids model treatment response of metastatic gastrointestinal cancers. Science. 359(6378):920–6.
48. US Food and Drug Administration. Artificial intelligence/machine learning (AI/ML) based software as a medical device (SaMD) action plan. Silver Spring (MD): FDA; 2021.
49. Coravos A, Khozin S, Mandl KD. (2019). Developing and adopting safe and effective digital biomarkers to improve patient outcomes. npj Digit Med. ;2(1):14.
50. Zehir A, Benayed R, Shah RH, Syed A, Middha S, Kim HR, et al. (2017). Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med. 23(6):703–13.
51. Kim JW, Botvinnik OB, Abudayyeh O, Birger C, Rosenbluh J, Shrestha Y, et al. (2016). Characterizing genomic alterations in cancer by complementary functional associations. Nat Biotechnol. 34(5):539–46.
52. Adalsteinsson VA, Ha G, Freeman SS, Choudhury AD, Stover DG, Parsons HA, et al. (2017). Scalable whole exome sequencing of cell free DNA reveals high concordance with metastatic tumour biopsies. Nat Commun. 8(1):1324.
53. Zviran A, Schulman RC, Shah M, Hill STK, Deochand S, Khamnei CC, et al. (2020). Genome wide cell free DNA mutational integration enables ultra sensitive cancer monitoring. Nat Med. 26(7):1114–24.
54. Holbeck SL, Camalier R, Crowell JA, Govindharajulu JP, Hollingshead M, Anderson LW, et al. (2017). The National Cancer Institute ALMANAC: a comprehensive screening resource for the detection of anticancer drug pairs with enhanced therapeutic activity. Cancer Res. 77(13):3564–76.
55. Preuer K, Lewis RPI, Hochreiter S, Bender A, Bulusu KC, Klambauer G. (2018). Deep Synergy: predicting anti cancer drug synergy with deep learning. Bioinformatics. 34(9):1538–46.
56. Gillette MA, Satpathy S, Cao S, Dhanasekaran SM, Vasaikar SV, Krug K, et al. (2020). Proteogenomic characterization reveals therapeutic vulnerabilities in lung adenocarcinoma. Cell. 182(1):200–25.
57. Boehm KM, Bhinder B, Raja VJ, Dephoure N, Bhatt DL. (2022). Harnessing multimodal data integration to advance precision oncology. Nat Rev Cancer. 22(2):114–26.
58. Frisoni GB, Barkhof F, Garibotto V, Moro E, Nordberg A, van Waalwijk van Doorn LJC. (2020). AMYPAD prognostic and natural history study: rationale and design. Alzheimers Dement. 16(10):1428–36.
59. European Medicines Agency. (2023). Reflection paper on the use of artificial intelligence (AI) in the medicinal product lifecycle. Amsterdam: EMA.
60. Lundberg SM, Lee SI. (2017). A unified approach to interpreting model predictions. Adv Neural Inf Process Syst. 30:4765–74.
61. Popejoy AB, Fullerton SM. (2016). Genomics is failing on diversity. Nature. 538(7624):161–4.
62. Mhaskar R, Rajan R, Ling E. (2020). Access to precision medicine for low income and middle income countries: a cross sectional analysis. BMJ Open. 10(3):e031925.
63. Walsh C, Shah H, Bhatt A, Bhatt J. (2021). Artificial intelligence in drug discovery and development. Drug Discov Today. 26(1):80–93.

64. Cao Y, Romero J, Olson JP, Degroote M, Johnson PD, Kieferová M, et al. (2019). Quantum chemistry in the age of quantum computing. Chem Rev. 119(19):10856–915.
65. Arute F, Arya K, Babbush R, Bacon D, Bardin JC, Barends R, et al. Quantum supremacy using a programmable superconducting processor. Nature. 2019;574(7779):505–10.
66. Singhal K, Azizi S, Tu T, Mahdavi SS, Wei J, Chung HW, et al. (2023). Large language models encode clinical knowledge. Nature. 620(7972):172–80.
67. Rieke N, Hancox J, Li W, Milletarì F, Roth HR, Albarqouni S, et al. (2020). The future of digital health with federated learning. npj Digit Med. 3(1):119.
68. Simm J, Klambauer G, Arany A, Steijaert M, Wegner JK, Gustin E, et al. (2021). Splitting chemical structure data sets for federated privacy preserving machine learning. J Cheminform. 13(1):81.
69. Ruffolo JA, Chu LS, Mahajan SP, Gray JJ. (2023). Fast, accurate antibody structure prediction from deep learning on massive set of natural antibodies. Nat Commun. 14(1):2389.
70. Lin Z, Akin H, Rao R, Hie B, Zhu Z, Lu W, et al. (2023). Evolutionary scale prediction of atomic level protein structure with a language model. Science.379(6637):1123–30.
71. Bento AP, Gaulton A, Hersey A, Bellis LJ, Chambers J, Davies M, et al. (2014). The ChEMBL bioactivity database: an update. Nucleic Acids Res.42(D1):D1083–90.
72. Bender A, Cortés Ciriano I, van Westen GJP, Mitchell JBO. (2020). Evaluation guidelines for machine learning tools in the chemical sciences. Nat Chem. 12(11):972–6.
73. Mullard A. (2023). AI drug discovery pipeline: separating hype from progress. Nat Rev Drug Discov. 22(3):183–4.
74. Coley CW, Thomas DA, Lummiss JAM, Jaworski JN, Breen CP, Schultz V, et al. (2019). A robotic platform for flow synthesis of organic compounds informed by AI planning. Science. 365(6453):eaax1566.
75. King RD, Rowland J, Oliver SG, Young M, Aubrey W, Byrne E, et al. (2009). The automation of science. Science. 324(5923):85–9.

CITATION OF THIS ARTICLE

Binaya Kumar S, Prerna G, Mohammad Z, Yogalakshmi R. Pharmacology 5.0: Intelligent Drug Discovery and the Rise of Predictive Therapeutics. Bull. Env. Pharmacol. Life Sci., Vol 15 [7] June 2026. 74-87